Haleon plc
HLN
Positions held
Your positionsHLN isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- Haleon operates in the healthcare sector, which is often resilient during economic downturns, providing a stable investment opportunity for long-term growth.
- Haleon's market cap stands at approximately $39 billion, indicating a strong presence in the drug manufacturing industry.
- The company has a dividend yield of 2.23%, offering investors a return on investment even in challenging market conditions.
- Haleon has a trailing P/E ratio of 18.1, which may suggest that the stock is overvalued compared to its earnings growth rate.
- The company's earnings growth has declined by 4.5% recently, raising concerns about its profitability and future performance.
- Haleon's score indicates a 'Strong Sell' signal with a score of -29.00, reflecting negative market sentiment and technical indicators.
Fundamentals
| Market cap | $40.72B | Enterprise value | $48.62B | Trailing P/E | 18.90 | Forward P/E | 14.98 |
| PEG | 2.09 | Price / book | 1.90 | Beta | 0.28 | Dividend yield | 2.14% |
| Revenue growth | 2.2% | Earnings growth | -4.5% | Gross margin | 65.6% | Operating margin | 23.9% |
| Profit margin | 14.6% | ROE | 10.1% | ROA | 5.1% | Debt / equity | 0.50 |
| Current ratio | 0.69 | Free cash flow | $1.80B | Analyst recommendation | buy | Mean target | $11.93 |
| 52w high | $11.28 | 52w low | $8.65 |
Quarterly
No data yet.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | $11.0B | $11.2B | $11.3B | $10.9B |
| Op margin | 21.9% | 19.6% | 17.7% | 16.8% |
| Net income | $1.7B | $1.4B | $1.0B | $1.1B |
| Gross margin | 64.2% | 60.7% | 59.7% | 60.6% |
| Gross profit | $7.1B | $6.8B | $6.7B | $6.6B |
| Operating income | $2.4B | $2.2B | $2.0B | $1.8B |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-05 · Goldman Sachs Top European Stock Picks Have a Hidden Perk for Income Investors
2026-10-03 · 3 British AI Healthcare Stocks With Revenue Up To £61 Billion
2026-09-28 · LCUT vs. HLN: Which Stock Is the Better Value Option?
2026-09-28 · J.P. Morgan flags negative catalyst at Haleon on weak sales momentum
2026-09-25 · Haleon tipped to cut sales growth guidance as cough and cold season clouds outlook
2026-09-24 · 3 British AI Stocks With Revenue Up To £61 Billion
2026-09-24 · Haleon is Buying Better Shelf Space, Can the Visibility Help it Against Procter & Gamble and Colgate-Palmolive?
2026-09-23 · Deutsche Bank stays bearish on Haleon as growth headwinds mount
2026-09-22 · Haleon Turns to Weight-Loss Drug Users for its Next U.S. Growth Opportunity
2026-09-19 · A drugmaker is gaining from the side effects of weight-loss drugs
2026-09-17 · Tums-Maker’s Sales Grow as Weight-Loss Drug Users Grapple With Uncomfortable Side Effects
2026-09-16 · Advil-maker Haleon boosts US sales by targeting consumers on weight-loss drugs
Price (daily)
Full chart · RSI · MACD · patterns